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Summary
Insulin-like growth factor-I (IGF-I) and IGF binding proteins (IGFBPs) are trophic factors for cartilage and have been shown to be chondropro-
tective in animal models of osteoarthritis (OA). IGFBP-5 is degraded in joint ﬂuid and inhibition of IGFBP-5 degradation has been shown to
enhance the trophic effects of IGF-I.
Objective: To determine the identity of IGFBP-5 protease activity in human OA joint ﬂuid.
Method: OA joint ﬂuid was puriﬁed and the puriﬁed material was analyzed by IGFBP-5 zymography.
Results: Both crude joint ﬂuid and puriﬁed material contained a single band of proteolytic activity that cleaved IGFBP-5. Immunoblotting of joint
ﬂuid for complement 1s (C1s) showed a band that had the same Mr estimate, e.g., 88 kDa. In gel tryptic digestion and subsequent peptide
analysis by LC-MS/MS showed that the band contained human C1s. A panel of protease inhibitors was tested for their ability to inhibit IGFBP-
5 cleavage by the puriﬁed protease. Three serine protease inhibitors, FUT175 and CP-143217 and CB-349547 had IC50’s between 1 and
6 mM. Two other serine protease inhibitors had intermediate activity (e.g., IC50’s 20e40 mM) and MMP inhibitors had no detectible activity
at concentrations up to 300 mM.
Conclusion: Human OA ﬂuid contains a serine protease that cleaves IGFBP-5. Zymography, immunoblotting and LC-MS/MS analysis indicate
that C1s is the protease that accounts for this activity.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Insulin-likegrowth factor-I (IGF-I) is apotent stimulant of chon-
drocyte extracellular matrix protein synthesis and growth1,2.
Following its synthesis in liver IGF-I is transported to target
tissues, such as cartilage, where it stimulates growth3. IGF-I
is also synthesized by cartilage and this locally synthesized
IGF-I stimulates epiphyseal growth4. Direct injection of growth
factor (GH) into the growth plate of hypophysectomized
animals stimulates IGF-I synthesis and cartilage growth.
Simultaneous administration of an IGF-I antibody results in at-
tenuation of the cartilage growth response5. In mice deletion
of hepatic IGF-I geneexpression reducesblood IGF-I concen-
trations by 80% but has a minimal effect on statural growth
(6% reduction) whereas if IGF-I synthesis in cartilage and
other tissues is eliminated growth is attenuated by 50%6,7.
In addition, growth plate chondrocytes in the proliferative
zone possess abundant IGF-I receptors and both growth
plate and articular chondrocytes respond to IGF-I in vitro
with increases in DNA and proteoglycan synthesis2,8.
Together, these ﬁndings support the conclusion that locally
produced IGF-I is an important cartilage growth factor.*Address correspondence and reprint requests to: David R.
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Carolina at Chapel Hill, CB# 7170, 8024 Burnett-Womack,
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547Treatment of canine osteoarthritis (OA) with IGF-I results
in articular cartilage preservation and exposure to other
cartilage growth factors enhances the cartilage response
to IGF-I9,10. In human OA there is upregulation of IGF-I syn-
thesis11. There is also increased IGF-I synthesis in the
synovium of inﬂamed joints and IGF-I augments chondro-
cyte proliferation after in vivo injury12,13. Furthermore ade-
noviral mediated gene transfer of IGF-I into joints has
been shown to have a protective function for articular chon-
drocytes in animal models of arthritis14e17.
IGF binding proteins (IGFBPs) are synthesized by articu-
lar cartilage both during normal growth and during repair
after injury12,18e20. Both IGFBP-3 and 5 have been shown
to be upregulated during the early phases of articular chon-
drocyte differentiation and then downregulated when the
cells become hypertrophic18. Upregulation of IGFBP-5 was
shown to be associated with enhanced IGF-I activation of
the PI-3 kinase pathway in growth plate chondrocytes21. In
OA articular cartilage, there is enhanced expression of
IGFBP-3, 4 and 520. The ratio between IGF-I and IGFBPs
appears to be important since disruption of the IGFBP-3/
IGF-I complex has been shown to enhance IGF-I actions22,
however, IGFBPs also perform an important storage func-
tion in the joint and if all binding activity is eliminated IGF-I
is a less effective growth stimulant. IGFBP-3 is abundant
on the surface of articular chondrocytes and in OA joints
and has been reported to make the cells refractory to IGF-I23.
However, in some studies IGFBP-5 enhanced both growth
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variable that regulates IGFBP-5 is proteolysis and
IGFBP-5 protease activity is increased in joint ﬂuid during
the development of arthritis24e27. Inhibition IGFBP-5 cleav-
age was shown to limit the amount of articular cartilage de-
struction in dogs during the development of OA. This was
associated with an increase in the amount of IGF-I in joint
ﬂuid as well as an increase in intact IGFBP-524. These ﬁnd-
ings suggest that in certain situations IGFBP-5 can act as
a reservoir for IGFs in cartilage and synovial ﬂuid and that
factors that regulate rate of IGFBP-5 cleavage may alter
the ability of this tissue to respond to IGF-I. Several prote-
ases have been shown to cleave IGFBP-528, however,
only complement 1s (C1s)24 and HTRA-130,31 have been
shown to be increased in OA. These studies were under-
taken to characterize the type of proteolytic activity that is
present in human OA joint ﬂuid and to determine the spe-
ciﬁc protease that accounts for this activity.
MethodsPURIFICATION OF PROTEASE ACTIVITY50 cc of Knee joint ﬂuid was obtained from patients with active OA. This
was deﬁned using the criteria of the American College of Rheumatology.
The patients were undergoing arthroscopy or knee replacement. All patients
gave informed consent. 50 ml of Joint ﬂuid was added to 450 ml of 0.05 M
Tris, pH 7.2 containing 1 M of ammonium sulfate and stored for 14 h at
4C then centrifuged 23,000 g for 20 min. The supernatant was loaded
onto a 4.4 3.5 cm butyl sepharose column-4 (Fast Flow Pharmacia Bio-
tech) that had been equilibrated with 0.07 M Tris, pH 7.2, 1 M ammonium sul-
fate. The column was washed with 2 column volumes of the equilibration
buffer and eluted with 0.025 M, Tris, pH 7.2 then the fractions were analyzed
for IGFB-5 proteolytic activity. The active fractions were pooled then loaded
onto a wheat germ agglutinin (WGA) afﬁnity column (1.6 5.0 cm) (Sigma)
equilibrated 0.025 M Tris, 4 mM CaCL2, 0.4 M NaCl pH 7.2. After washing
(2 column volumes) the activity was eluted with 0.5 M N-acetyl-D-glucos-
amine. The fractions which had the greatest activity were pooled, diluted
1:2.5 with 25 mM Tris, pH 7.2, 4 mM CaCl2, 2 mM MnCl2, 0.4 M NaCl then
loaded onto a concanavalin-A (Con-A) agarose column (1 9 cm) (Sigma).
After washing (5 column volumes) the activity fractions were eluted with
0.25 M, methyl-a-D-glycopyranoside and 0.25 M methyl-a-D-mannopyrano-
side. The fractions with proteolytic activity were pooled prior to SDS-PAGE
separation.ASSAY OF IGFBP-5 PROTEOLYTIC ACTIVITY AND
IMMUNOBLOTTING OF C1S10 ml of each fraction was incubated with 0.05 ml of 0.05 M Tris, 4 mM
CaCL2, pH 7.2, for 16 h at 37
C containing 118 ng of pure human
IGFBP-532. The incubation of the reaction was terminated by adding
50 ml of 4 Lammeli sample buffer. The amounts of intact and cleaved
IGFBP-5 were determined using SDS-PAGE followed by immunoblotting.
50 ml of the mixture was electrophoresed through a 12.5% gel and trans-
ferred to an Immobilon ﬁlter. The ﬁlters were probed using a 1:2000 dilution
of a rabbit polyclonal antiserum32. The immune complexes were detected
using enhanced chemiluminescense33. The fractions that contained proteo-
lytic activity were analyzed by immunoblotting for C1s using a 1:1000
dilution of rabbit anti C1s antiserum28.
To determine the effect of puriﬁed protease inhibitors, a mixture of
0.05 ml of 0.05 M Tris, 4 mM CaCl2, pH 7.2, 118 ng of IGFBP-5 and in-
hibitor concentrations between 0.2 and 300 mM were incubated for 16 h
at 37C. Either 1.6 ml of crude joint ﬂuid or 2 ml of material that had been
puriﬁed as described previously was used as a source of the protease.
The incubation was terminated by adding 45 ml of 4 Laemmli sample
buffer and the samples were immunoblotted for IGFBP-5 as described
above. The IGFBP-5 antibody detects both intact IGFBP-5 and the major
22 kDa fragment32. The immunoblots were developed using a goat anti-
rabbit IgG alkaline phosphatase conjugate and chemiluminescense. Pro-
teins were detected using enhanced chemiluminescense supersignal,
CL-HRP system (Pierce, Rockford, Ill) and Kodak XAR ﬁlm. Scanning
densitometry was performed using an AGFA Scanner (Brussels, Bel-
gium) and the results were analyzed using NIH Image version 1.61.
To calculate the IC50 for each inhibitor the results of at least two sepa-
rate experiments were analyzed.
Some chromatographic fractions were also immunoblotted for HTRA-1
using rabbit polyclonal antiserum that was prepared using two synthetic
HTRA-1 peptides as described previously29.JOINT FLUID ZYMOGRAPHY10 mcg of IGFBP-5 was mixed with 4 ml of acrylamide gel solution (10%
gel) and the gel was polymerized. The samples of synovial ﬂuid (1.6 ml) or
Con-A column eluate (12 mg) were electrophoresed at 22C. After washing
in 2.5% TritonX-100 at 4C for 1 h the gel was incubated overnight in
0.05 M Tris, 4 mM CaCl2 pH 7.4 at 37
C to allow for proteolysis and capillary
transfer of the IGFBP-5 fragments to a polyvinylidene ﬂuoride (PVDF)
membrane. The membrane was immunoblotted using a 1:2000 dilution of
IGFBP-5 antiserum as described above. The electrophoretic mobility of the
bands that were detected was compared with the prestained molecular weight
standards (Life Technologies).PROTEIN IDENTIFICATION BY MASS SPECTROMETRYThe material that had been puriﬁed through the Con-A afﬁnity chromatogra-
phy step (250 ml) was concentrated and the buffer exchanged into 2 Lammeli
sample buffer using an Ultrafree 0.5 ml centrifugal ﬁlter Biomax 10k/MWL (Milli-
pore). 250 mg of protein in 50 ml was loaded; the proteins were separated by
SDS-PAGE, 7.5% gel. The gel was stained with 0.1% Coumassie blue R250
(Sigma) in 10% acetic acid then destained in 50% methanol for 2 h. The bands
with mass estimates of 88 and 92 kDa were excised, washed 3 in 0.2 M Tris
pH8.0/50%acetonitrite then incubated in 250 ml of 0.1 MTris, pH8.0with 2.0 mg
trypsin and 4 mM dithiothreitol (DTT) for 14 h at 37C. Following sonication
(30 min RT) 1.0 mg of trypsin was added and the incubation continued for 5 h
at 37C. The peptides were extracted in 100 ml of 0.1 M Tris, pH 8. This was re-
peated using 400 mcl of buffer followed by two extractions with 400 mcl of 60%
acetonitrile, 0.2% triﬂuoro acetic acid (TFA). The four extracts were pooled and
concentrated 4.
The samples were the analyzed on a Q-TOF (quadrapole time-of ﬂight)
mass spectrometer (Waters, Beverly, MA, USA) coupled to a CapLC system
(Waters, Milford, MA, USA). 49 ml of sample was injected via ‘‘microliter
pickup’’ mode and desalted and concentrated on-line through a peptide Cap-
Trap cartridge (Microm BioResources, Auburn, CA). The samples were de-
salted at high ﬂow (40 ml/min). The peptides were separated on a Pepmap
column (75 mm 150 mm, 3 mm particle size) (LC packings, San Francisco,
CA, USA). Separation was achieved using a 180 min step gradient of 95%
water, 0.1% formic acid to 75% acetonitrile, 0.31% formic acid. The ﬂow
rate was increased linearly with organic mobile phase from 250 to 400 nl/min.
Data dependent MS/MS experiments were performed using a modiﬁed
nanospray source designed to hold a distally coated picotip (360 mm
OD 20 mm ID 10 mm tip diameter) (New Objective, Cambridge, MA).
The instrument parameters were: capillary voltage, 1.4e1.6 kV; cone volt-
age, 35 V, and source block temperature 140C. The collision energy was
determined in real time based on the mass and charge state of the peptide.
Charge state recognition was used to switch into MS/MS mode on all doubly,
triply, and quadruply charged ions above a certain threshold. The mass
spectrometer monitored up to three components per survey scan. Spectra
were acquired in MS mode at 1 s/scan and MS/MS mode at 2 s/scan. The
MS switched back from MS/MS to MS based on either of two criteria: 6 s
or maximum intensity of 3000. Major trypsin autolysis ions were excluded.
Tuning and calibration of the Q-TOF mass spectrometer were performed
while infusing 1 pmol/ml porcine somatotropin (PST) tryptic digest into the
mass spectrometer. The data was processed by ProteinLynx version 3.5
(Waters, Beverly, MA) to generate searchable .pkl ﬁles. These ﬁles were
searched using the search engine MASCOT (Matrix Science, Ltd.).PROTEASE ENZYMATIC INHIBITION ASSAYSThe C1s assay was a chromogenic assay modiﬁed from34. The inhibitors
that were tested were synthesized at Pﬁzer CP-349547, Serine Protease In-
hibitor 1, CP-013043, CP-143217, CP-669685, PHA-00737785 and C1s Pro-
tease Inhibitor or they were purchased. FUT175 (Waterstone Technology,
Indianapolis, IN) Adam 12 Inhibitor and 1,10-phenanthroline (Sigma, St
Louis, MO), and Serine Protease Inhibitor 2 (Chembridge Corp, San Diego,
CA). Brieﬂy, 800 ng puriﬁed C1s (Calbiochem #204879) and the various
inhibitors, dissolved in dimethyl sulfoxide (DMSO) (0.5%), were incubated
in 0.1 ml of 50 mM TriseHCL, 4 mM CaCl2, pH 7.4 for 30 min. Chromogenic
substrate (Diapharma #S-2765) 1.0 mM was added and absorbance read at
405 nm. The thrombin protease inhibition was measured using the chromo-
genic substrate, S-2238 (Diapharma) following the manufacturer’s methods
listed in the Chromogenix Substrate Booklet.
Results
Analysis of the protease activity by IGFBP-5 zymography
showed that joint ﬂuid contained a single band (Mr 88 kDa)
that cleaved IGFBP-5 [Fig. 1(A)]. Following the three step
puriﬁcation in which the speciﬁc activity of the proteolytic
activity was increased approximately 2000-fold, repeat
Fig. 1. (A) Zymographic analysis of IGFBP-5 protease activity in
C1s in crude and puriﬁed joint ﬂuid. Human joint ﬂuid was puriﬁed
as described in Methods. The ﬁgure shows the IGFBP-5 protease
activity as assessed by IGFBP-5 zymography in crude synovial
ﬂuid (lane 1) and highly puriﬁed ﬂuid (lane 2). A separate sample
of the highly puriﬁed preparation is shown in lane 3. A control sam-
ple of conditioned medium from a tumor cell line that contained both
C1s and unidentiﬁed IGFBP-5 protease other than C1s (lower
arrow) is shown for comparison in lane 4. The human synovial
ﬂuid samples contain a single 88 kDa band as denoted by the
upper arrow. No other bands were detected. (B) Assessment of
C1s abundance by immunoblotting. The same joint ﬂuid that was
analyzed in (A) was also analyzed by immunoblotting for C1s.
The results show that a single band is detectible in crude joint ﬂuid
(denoted by arrow) that has an Mr estimate corresponding to the
88 kDa band noted on zymography (panel A, lane 1). An aliquot
of the active material that was concentrated during each chromato-
graphic step was analyzed in lanes 2e6. Lane 2, butyl sepharose
eluate, lane 3, WGA ﬂow through, lane 4 WGA eluate, lane 5,
Con-A ﬂow through, lane 6, Con-A eluate.
Fig. 2. IGFBP-5 cleavage. The crude joint ﬂuid and the puriﬁed ma-
terial obtained after each puriﬁcation step were incubated with
a known concentration of intact IGFBP-5 as described in Methods.
The products of the reaction were analyzed by immunoblotting for
IGFBP-5. Lane 1, human IGFBP-5 standard, 5 ng. Lane 2, non-
puriﬁed human synovial ﬂuid. The arrows denote the position of in-
tact IGFBP-5 (upper) and the position of the IGFBP-5 fragments
(lower). The chromatographic fractions are shown in lanes 3e9.
Lane butyl sepharose ﬂow through, lane 4, butyl sepharose eluate,
lane 5, WGA ﬂow through, lane 6, WGA eluate. Lane 7 Con-A
eluate 5 ml, lane 8 Con-A eluate 2 ml, lane 9 Con-A ﬂow through.
549Osteoarthritis and Cartilage Vol. 17, No. 4analysis showed the identical zymographic band and no
new zymographic bands were detected [Fig. 1(A)]. This
Mr estimate corresponded to the Mr estimate of C1s which
cleaves IGFBP-524,28. Immunoblotting for C1s showed that
both the joint ﬂuid and the puriﬁed material contained a sin-
gle immunoreactive band with an Mr estimate of 88 kDa
[Fig. 1(B)].
To determine if the pattern of proteolytic cleavage changed
following puriﬁcation, the molecular sizes of the IGFBP-5
cleavage fragments were estimated using the same puriﬁed
chromatographic fractions. Multiple bands ranging in Mr es-
timates from 19 to 24 kDa were detected when either the
non-puriﬁed joint ﬂuid or the partially puriﬁed material was
used as a source of the protease activity (Fig. 2). The anti-
body is relatively speciﬁc for the N-terminal region of
IGFBP-5 and therefore C-terminal cleavage fragments that
were present in low concentrations may not be detected.
To conﬁrm that the 88 kDa band contained C1s and de-
termine if other proteases that were present the partiallypuriﬁed material was further fractionated by SDS-PAGE.
Two bands Mr 90 and 86 kDa were excised, digested with
trypsin and the resulting peptides were analyzed using
mass spectrometry. MS/MS data was searched against
the Swiss-Prot mammalian database using the search en-
gine MASCOT. C1s was identiﬁed in each band. The only
other serine protease that was detected was complement
1r which we had shown previously did not cleave IGFBP-528.
No peptides corresponding to tryptic fragments of the
metalloproteases, or cysteine proteases were detected.
Speciﬁcally HTRA-1 was not detected.
To further determine if the protease activity in unfractio-
nated joint ﬂuid and the puriﬁed preparation had similar
properties, the effects of several protease inhibitors on
IGFBP-5 proteolysis were quantiﬁed. The compounds
were tested between 0.1 and 360 mM. The amount of puri-
ﬁed enzyme that was used was determined by quantifying
the amount that was required to degrade 90% of the
IGFBP-5 in 4 h. This was compared to the IGFBP-5 proteo-
lytic activity of commercially available preparation of C1s
(Table I). The results showed that for non-puriﬁed joint ﬂuid
3 of the 11 inhibitors that were tested were highly active with
IC50’s ranging between 0.5 and 6 mM (Table I) (Fig. 3). All
three compounds are serine protease inhibitors. FUT175 is
a potent C1s inhibitor and CP-143217 is highly active
against thrombin. CP-349547 and C1s Protease Inhibitor
had intermediate activity. Serine Protease Inhibitor 1 had
a biphasic response being highly active at 2 mM then lost
activity until 100 mM was added. This is consistent with con-
centration dependent aggregation and subsequent loss of
activity. Serine Protease Inhibitor 2 was active but aggre-
gated at high concentrations (Table I). An MMP 2, 9 and
13 inhibitor showed no inhibition at 350 mM and an Adam
4 inhibitor as well as other MMP inhibitors showed no
inhibition at this concentration. An Adam 12 Inhibitor had
some activity at 360 mM but did not achieve 50% inhibition.
Therefore FUT175, CP-143217 and Serine Protease
Inhibitor 1 were the most active for inhibiting the IGFBP-5
protease activity in crude joint ﬂuid. When these com-
pounds were tested using the puriﬁed joint ﬂuid preparation
similar results were obtained with the exception of Serine
Protease Inhibitor 1 (Fig. 4). CP-349547, FUT175, and
CP-143217 were the most active and their IC50’s were
between 1 and 6 mM. Therefore FUT175 and CP-143217
had values that were similar to these obtained using crude
Table I
Protease inhibitors
Compound information/structure Thrombin
IC50 (mM)
Human joint
ﬂuid IC50 (mM)
Puriﬁed protease
IC50 (mM)
Puriﬁed C1s
IC50 (mM)
CP-349547 serine protease inhibitor 0.121 20 4 1
N
O
O
HO
O
N
NH2
NH
48
Serine protease inhibitor 1*
0.5 100 >100
CP-013043 serine protease inhibitor 0.140 >360 100 >100
CP-143217 serine protease inhibitor 0.281 6 6 1
49O
NH2
NH
O
N
H
H2N
NH
FUT175 serine protease inhibitor
3400 3 1 0.070
HN
HN
O O
O
O
HO
Br
50
Adam 12 inhibitor
Not tested >360 No inhibition >100
N
N
51
1,10-phenanthroline, MMP inhibitor
Not tested No inhibition No inhibition Not tested
N
S
O
O
HO
N
H
O
OH
O
Cl
F 52
CP-669685 Adam 4 inhibitor
Not tested No inhibition No inhibition >100
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Table I (continued )
Compound information/structure Thrombin
IC50 (mM)
Human joint
ﬂuid IC50 (mM)
Puriﬁed protease
IC50 (mM)
Puriﬁed C1s
IC50 (mM)
N NH
O
O O
O
Br
Serine protease inhibitor 2*
Not tested 90 80* Not tested
S
O
O
N
H
O
O
HO
N
N
F
F
F
F
F 53
PHA-00737785, MMP 2, 9, 13 inhibitor
Not tested No inhibition No inhibition >100
N
N
NS
S
N
HN
S
NH2
54
C1s protease inhibitor
>30 30 25 1.03
*Induced aggregation.
551Osteoarthritis and Cartilage Vol. 17, No. 4joint ﬂuid (Table I). Compound CP-349547 had lower IC50
(4.0 mM) compared to its IC50 using crude synovial ﬂuid.
These results estimated from scanning densitometry are
consistent with inhibition observed in a biochemical assay
using puriﬁed commercially available serum C1s (Table I).
The three compounds with the greatest inhibitory activity
for the puriﬁed protease all had IC50 values of 1 mM or
less. These results further support the conclusion that the
protease activity in partially puriﬁed material is the same
as that in unfractionated joint ﬂuid. HTRA-1 was clearly
detectible in the crude joint ﬂuid by immunoblotting
(Fig. 5). To conﬁrm that it had been removed during the pu-
riﬁcation process the chromatographic fractions (analyzed
for C1s in Fig. 1) were immunoblotted for HTRA-1. A single
band (Mr estimate of 28 kDa) was detected. This corre-
sponds to the Mr estimate of the active fragment of
HTRA-1 that contains its protease activity29. This band
was removed during puriﬁcation and a band corresponding
to this molecular weight was not detected by zymography.
Moreover, based on LC-MS/MS analysis there was no
detection of HTRA-1 in either of the two bands with
zymographic activity (Mr 88e92 kDa).Discussion
Inhibition of C1s activity in dog joint ﬂuid results in in-
creases in intact IGFBP-5 and IGF-I24. Inhibiting cleavage
of IGFBP-5 also resulted in a protective effect for articular
cartilage in a dog model of OA24. However, there have
been discrepant ﬁndings regarding which serine proteases
are present and active in human joint ﬂuid. Furthermore
several proteases including HTRA-129 Adam 935, Adam
12S36, PAPP2A37 MMP 2 and 938 have been shown to
cleave IGFBP-5. Our ﬁndings demonstrate that C1s is likely
to account for most of the IGFBP-5 protease activity in hu-
man OA ﬂuid. Several ﬁndings support this conclusion.
Mass spectrometric identiﬁcation of the proteins from the
SDS gel band that corresponded in molecular weight to
the IGFBP-5 zymographic activity showed that it contained
C1s. Low concentrations (e.g., 1e6 mM) of serine protease
inhibitors with a high speciﬁcity towards pure C1s inhibited
cleavage of IGFBP-5 by crude joint ﬂuid. Finally the cleav-
age fragments generated by the puriﬁed material that was
enriched in C1s and those generated by exposure to joint
ﬂuid appeared to be of similar molecular size. Taken
Fig. 3. (A) The effect of protease inhibitors on IGFBP-5 cleavage by proteases in human synovial ﬂuid. Only those inhibitors that were active
using reasonably low concentrations are shown. The effect of non-puriﬁed synovial ﬂuid is shown in lane 1. Lanes 2e12 contained the same
amount of synovial ﬂuid. Compound CP-143217 is shown in lanes 2e5, lane 2, 45 mM, lane 3, 24 mM, lane 4, 6 mM, lane 5, 2 mM. Lanes 6e8,
FUT175 , lane 6, 24 mM, lane 7, 6 mM, lane 8, 2 mM. Lane 9, control HSF, lanes 10e13, CP-349547, lane 10, 360 mM, lane 11, 45 mM, lane 12,
6 mM, lane 13, 2 mM. The arrows indicate the position of intact IGFBP-5 (upper) and the cleavage products (lower). (B) Effect of inhibitors on
IGFBP-5 proteolysis by human synovial ﬂuid. Additional inhibitors were tested as in Fig. 3. Lanes 1e3, C1s Protease Inhibitor, lane 1, 350 mM,
lane 2, 70 mM, lane 3, 5 mM, lane 4, control HSF, Lanes 5e8, Serine Protease Inhibitor 1, lane 5, 45 mM, lane 6, 2 mM, lane 7, 0.5 mM, lane 8,
0.1 mM, lane 9, control HSF.
Fig. 4. (A) Effect of inhibitors on cleavage of IGFBP-5 by the puri-
ﬁed enzyme. The enzyme preparation that had been puriﬁed
through the concanavalin-A step was used as a source of protease
and the effect of the same inhibitors that were analyzed in Fig. 3
was assessed. Lanes 1e9 puriﬁed protease, lanes 1e3, C1s Pro-
tease Inhibitor, lane 1, 100 mM, lane 2, 25 mM, lane 3, 5 mM, lane
4 control, puriﬁed protease. Lanes 5e8 FUT175, lane 5, 100 mM,
lane 6, 10 mM, lane 7, 2.5 mM, lane 8, 0.62 mM, lane 9 control pro-
tease. (B) Effect of protease inhibitors on the activity of the puriﬁed
enzyme. As in Fig. 5 the enzymatic activity that had been puriﬁed
through the Con-A step was incubated with the protease inhibitors
and IGFBP-5 as described in Methods. Lanes 1e12 puriﬁed prote-
ase, lanes 2e4, CP-143217, lane 2, 100 mM, lane 3, 6 mM, lane 4,
2 mM, lanes 5e8 Serine Protease Inhibitor 1, lane 5, 100 mM,
lane 6, 45 mM, lane 7, 0.5 mM, lane 8, control protein, lanes 9e11
CP-349547, lane 9, 24 mM, lane 10, 6 mM, lane 11, 2 mM, lane
12, control puriﬁed protease. The arrows show the position of
intact IGFBP-5 (upper) and the 22 kDa fragment (lower).
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tion resulted in improvement in joint architecture in a dog
model of OA, the ﬁndings suggest that inhibition of
IGFBP-5 proteolysis by inhibiting C1s may be an approach
to improving articular cartilage protection during the devel-
opment of OA.
IGF-I stimulates proteoglycan synthesis, chondrocyte cell
proliferation and protein synthesis1,2,4,9,10,23. Studies in an-
imal models have shown that direct injection of IGF-I into
the joint or administration of GH which results in an increase
in the concentration of IGF-I in joint ﬂuid are trophic for
growth plate cartilage during normal development and for
articular cartilage during the development of OA13,39e42.
IGF-I synergizes with other growth factors such as epider-
mal growth factor (EGF), TGFa and ﬁbroblast growth factor
(FGF) to enhanced proteoglycan synthesis and cartilage re-
pair. Gene therapy using adenovirus-associated IGF-I
transfection experiments has shown that overexpression
of IGF-I in experimental models of OA is protective for artic-
ular chondrocytes13e15. Strategies to decrease cytokine
levels and inﬂammatory cell activation in combination with
IGF-I therapy produce additive improvement in cartilage
matrix accumulation43. Osteogenic protein-I (OP-1) en-
hances the effects of IGF-I on articular cartilage and IGF-I
synthesis is upregulated during articular chondrocyte repair
in several animal models of arthritis44. These ﬁndings sug-
gest that restoration of IGF-I to normal levels or attainment
of supraphysiologic concentrations in the periarticular
space during repair may lead to improved outcomes.
The role of IGFBPs in modulating IGF-I action in cartilage
has yielded conﬂicting results. Fernihough et al. demon-
strated that in a dog model of OA IGFBP-3 and 4 were up-
regulated and these changes were accompanied by
increases in IGF-I45. Iwanaga et al. using immunohisto-
chemistry and in situ hybridization showed increased ex-
pression of IGFBP-3, 4 and 5 in OA articular cartilage as
compared to control20. Large increases in the concentra-
tions of IGFBPs in extracellular ﬂuid can limit IGF-I access
Fig. 5. Abundance of HTRA-1 during puriﬁcation. The fractions that
were analyzed for IGFBP-5 protease activity at each puriﬁcation
step were analyzed for the abundance of HTRA-1 by immunoblot-
ting as described in Methods. Lane 1, non-puriﬁed joint ﬂuid, lane 2,
WGA column fall through, lane 3, WGA eluate, lane 4, Con-A, fall
through, lane 5, Con-A eluate. The arrows denote the position of
the active fragment of HTRA-1 that contains the protease activity.
Lane 6 shows an intact HTRA-1 standard for comparison. The
same amount of total protein that was immunoblotted for C1s
was also immunoblotted for HTRA-1. The arrow denotes the posi-
tion of the major cleavage fragment of HTRA-1 that contains the
catalytic activity of the enzyme31. The results show that most of
the HTRA-1 activity is eliminated in the ﬂow through fractions
from the wheat germ, agglutin and the Con-A columns. No
HTRA-1 immunoreactive fraction corresponds to the position of
the zymographic activity noted in Fig. 1.
553Osteoarthritis and Cartilage Vol. 17, No. 4to receptors. DeCeunick et al. showed that inhibition of IGF-
I association with IGFBP-3 resulted in improvement in pro-
teoglycan synthesis in human OA cartilage suggesting that
IGFBP-3 was inhibiting IGF-I actions22. However, studies
by Duan et al. suggested that IGFBP-3 had an important
positive modulatory role of IGF-I activity in chondrogenesis
during development46. Kiepe et al. reported that IGFBP-1,
2, 4 and 6 act exclusively as growth inhibitors of cartilage
cells in vitro, however, they obtained more complex results
with IGFPB-3 showing that if it was preincubated with
growth plate chondrocytes and then IGF-I was added it
could potentiate the effects of IGF-I whereas if a molar ex-
cess of IGFBP-3 was added together with IGF-I it inhibited
IGF-I action21. In contrast to these other binding proteins,
these investigators determined that IGFBP-5 enhanced
IGF-I stimulated growth plate chondrocyte proliferation.
These investigators determined that IGF-I induced IGFBP-
5 expression in cultured chondrocytes and that the increase
led to enhanced chondrocyte differentiation. They also
showed that IGFBP-5 potentiated the ability of IGF-I to en-
hance AKT activation21. Overexpression of IGFBP-5 alone
without IGF-I did not enhance chondrocyte proliferation or
differentiation.
The most plausible mechanism accounting for these ef-
fects is that when IGFBP-5 binds to extracellular matrix
components its afﬁnity is lowered greater than 10-fold for
IGF-I and this results in more favorable equilibrium between
the IGF-I that is bound to IGFBP-5 and the IGF-I receptor47.
The concomitant association of IGF-I with IGFBP-5 protects
IGF-I from being cleared rapidly from the joint space thus
prolonging its ability to enhance cartilage repair. Therefore
maintenance of a relatively high concentration of low afﬁn-
ity, intact IGFBP-5 provides a reservoir for IGF-I and this
may be important for an anabolic chondrocyte response.
Identiﬁcation of the protease that is degrading IGFBP-5
in cartilage has been difﬁcult due to the multiplicity of
proteases that are present during development of OA. Met-
alloproteases, serine proteases and cysteine proteases
have all been shown to be activated. Multiple types of pro-
teases including proteases from all three major classeshave been shown to degrade IGFBP-5, but studies with pro-
tease inhibitors using a variety of physiologic ﬂuids related
to OA, i.e., culture supernatants, OA joint ﬂuid or cartilage
extracts and synovial cell culture ﬂuid, have shown that in-
hibition of serine proteases results in increases in IGF-I con-
centrations. The serine proteases that have been implicated
in OA have focused on the urokinase-plasminogen system.
Although components of that system can degrade IGFBP-5,
studies to identify IGFBP-5 proteases in joint ﬂuid have not
conﬁrmed that they account for the IGFBP-5 proteolytic
activity.
A serine protease that deserves special consideration is
HTRA-1. Puriﬁed HTRA-1 degrades IGFBP-529 and
HTRA-1 is present in human OA joint ﬂuid. Two studies
have shown that HTRA-1 is upregulated following articular
cartilage damage in experimental animal models of arthritis
and in human OA joint ﬂuid30,31. Grau et al. demonstrated
that HTRA-1 was increased sevenfold in synovial ﬂuid
from rheumatoid and OA patients31. We could not conﬁrm
that HTRA-1 accounted for the IGFBP-5 protease activity
in joint ﬂuid. The electrophoretic mobility of HTRA-1 was
very different from the band accounted for by zymographic
activity. Secondly immunoblotting of the joint ﬂuid material
at each puriﬁcation step for HTRA revealed that most of
the immunoreactivity was removed during the ﬁnal puriﬁca-
tion step, whereas the IGFBP-5 protease activity was
retained. Third, mass spectrometry sequence analysis
showed that the gel band that contained the proteolytic
activity that accounted for IGFBP-5 protease activity did
not contain HTRA-1. Finally speciﬁc protease inhibitors
that had poor activity against puriﬁed HTRA-1 (data not
shown) were potent inhibitors of the IGFBP-5 protease
activity in crude joint ﬂuid. These ﬁndings suggest that al-
though HTRA-1 is present in joint ﬂuid and is proteolytically
active, it is not primarily responsible for degrading IGFBP-5.
This could be due to afﬁnity differences, that is the afﬁnity of
C1s for IGFBP-5 may be substantially higher than HTRA-1
or to the presence of endogenous inhibitors in joint ﬂuid that
preferentially alter the activity of HTRA-1 as opposed to
C1s. In support of differences in afﬁnity, C1s concentrations
as low as 3 nM degrade IGFBP-528 whereas 100 nM
HTRA-1 was required to detect signiﬁcant activity29.
In summary, our ﬁndings support the conclusion that C1s
accounts for the proteolytic activity in human OA ﬂuid for
IGFBP-5. Because increasing the amount of intact
IGFBP-5 increases the total IGF-I concentration and en-
hances IGF-I actions in cell types that are present in the
joint space, it appears to be chondroprotective in experi-
mental animal models of OA. This suggests that speciﬁc
strategies to inhibit C1s activity may positively modulate
the reparative response in human OA.Conﬂict of interest
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